On Mar. 18, 2020, Eli Lilly announced its scientists were partnering with the Indiana State Department of Health (ISDH), with support from the Food and Drug Administration (FDA), to accelerate testing in Indiana for SARS-CoV-2, the virus that causes COVID-19.

Lilly will use its specialized research laboratories to analyze samples taken in Indiana healthcare facilities, including nursing homes and emergency rooms. Assuming the company can continuously access required diagnostic reagents, this should start to expand the state’s ability to conduct testing and receive a timely diagnosis of individuals who suspect they may be carrying the virus. As Lilly’s testing capacity expands, Lilly and ISDH will work together to maximize the impact of broader testing.

In addition, Lilly is piloting drive through testing that may eventually be able to test patients outside of a healthcare facility to avoid spread of the virus. The company hopes to have additional details in the coming days.